CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
About this item
Full title
Author / Creator
Wang, Canming , Wang, Yukai , Chen, Jinxia , Wang, Yi , Pang, Chuhong , Liang, Chen , Yuan, Li and Ma, Yubo
Publisher
London: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Background The investigational use of zolbetuximab (IMAB362), a groundbreaking monoclonal antibody medication targeting claudin 18.2 (CLDN18.2), for treatment of advanced gastrointestinal cancers is currently underway. The unclear clinicopathological characteristics and tumour immune microenvironment of CLDN18.2-positive gastric cancer (GC) make it...
Alternative Titles
Full title
CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_57282cf406204a6198cb9b79413eeb9c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_57282cf406204a6198cb9b79413eeb9c
Other Identifiers
ISSN
1471-230X
E-ISSN
1471-230X
DOI
10.1186/s12876-023-02924-y
